Insulin Glargine - Toujeo - Diabetes Mellitus
You are here : Home > Formulary Search > Insulin Glargine - Toujeo - Diabetes Mellitus
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Blue
Formulations :
- Pre-filled pen
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Initiation by diabetes consultants or GPs with a specialist interest in diabetes. For use in poorly controlled patients.
Documentation
Policy Statement
Safety Information
PAD Profile
ChemicalSubstance :
Insulin Glargine - Toujeo
Indication :
Diabetes Mellitus
Group Name :
Insulin
Keywords :
High-strength insulins, high strength insulins, lipohypertrophy, cutaneous amyloidosis
Brand Names Include :
Toujeo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
7
Other Indications
Below are listed other indications that Insulin Glargine - Toujeo is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Diabetes Mellitus.
- Acarbose
- Alogliptin
- Alogliptin/metformin
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Canagliflozin/metformin
- Dapagliflozin
- Dapagliflozin/metformin
- Diazoxide
- Dulaglutide
- Empagliflozin
- Empagliflozin/metformin
- Ertugliflozin
- Exenatide
- Glibenclamide
- Gliclazide
- Glimepiride
- Glipizide
- Glucose
- Glyxambi (Linagliptin/empagliflozin)
- Insulin Aspart - Fiasp
- Insulin aspart - NovoRapid
- Insulin Aspart - Trurapi
- Insulin degludec
- Insulin degludec with liraglutide
- Insulin detemir
- Insulin glargine - Abasaglar
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Insulin Lispro - Humalog
- Insulin Lispro - Lyumjev
- Insulin pump - Type 1 diabetes
- Isophane (neutral insulin) - hypurin porcine 30/70
- Isophane Insulin - Humulin I
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Linagliptin
- Linagliptin/metformin
- Liraglutide
- Metformin hydrochloride
- Metformin hydrochloride/pioglitazone
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Pioglitazone hydrochloride
- Repaglinide
- Saxagliptin
- Saxagliptin/dapagliflozin
- Semaglutide
- Sitagliptin
- Soluble insulin - Hypurin porcine neutral
- Soluble insulin - Actrapid
- Soluble insulin - Humulin S
- Sotagliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Tirzepatide
- Tolbutamide
- Vildagliptin
Committee Recommendations (2)
MHRA Safety Alert
Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site. Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.
Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below
The PCN recommends the use of Toujeo (insulin glargine 300units/ml) in type 2 diabetes in the following circumstances:
A: To be initiated by diabetes consultants or those GPs with specialist interest in diabetes, only in those poorly controlled patients:
Who do not reach their target HbA1c because of significant hypoglycaemia
OR
Who experience significant hypoglycaemia on Neutral Protamine Hagedorn (NPH) and insulin detemir or glargine (100units/ml) irrespective of the level of HbA1c OR
Who cannot use the device needed to inject NPH and insulin detemir or glargine (100units/ml) but who could administer their own insulin safely and accurately if a switch to one of the long acting insulin analogues was made OR
Who need help from a carer or healthcare professional to administer insulin injections and for whom having a 3 hour window for daily administration is essential.
B: For those patients currently receiving Humulin R U-500, consider switch to Toujeo
A: To be initiated by diabetes consultants or those GPs with specialist interest in diabetes, only in those poorly controlled patients:
Who do not reach their target HbA1c because of significant hypoglycaemia
OR
Who experience significant hypoglycaemia on Neutral Protamine Hagedorn (NPH) and insulin detemir or glargine (100units/ml) irrespective of the level of HbA1c OR
Who cannot use the device needed to inject NPH and insulin detemir or glargine (100units/ml) but who could administer their own insulin safely and accurately if a switch to one of the long acting insulin analogues was made OR
Who need help from a carer or healthcare professional to administer insulin injections and for whom having a 3 hour window for daily administration is essential.
B: For those patients currently receiving Humulin R U-500, consider switch to Toujeo